
|Articles|September 7, 2012
Safety Tolerability footer references
Advertisement
References 1. Data on File, 309560. AstraZeneca Pharmaceuticals LP, Wilmington, DE. 2. Di Leo A, Jerusalem G, Petruzelka L, et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with
fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer [published errata
appears in
J Clin Oncol.
2011;29(16):2293]
J Clin Oncol
. 2010;28(30):4594-4600. 3. FASLODEX [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2010.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
Prophylaxis and Practical Implementation of the COPERNICUS Approach
2
Palbociclib Maintenance Extends PFS in HR+/HER2+ Advanced Breast Cancer
3
New ASCO Guideline Offers Recommendations for Smoldering Multiple Myeloma
4
Fecal Microbiota Transplantation Shows Feasibility in Metastatic RCC
5


































